Research · 2026-04-17
Scientific lead: Alice Kay, Ph.D.
Retatrutide FDA status and TRIUMPH
Direct answer
Where investigational retatrutide stands with the FDA and ongoing TRIUMPH studies. Research overview of public programs — not a catalogue listing.
Scope
Metabolic & energy-signaling models. Incretin, mitochondrial, and secretagogue literature. These notes summarize published models — they are not catalog pages.
Reviewer: Alice Kay, Ph.D., scientific lead. This note does not claim that the reviewer authored any cited paper.
Research-use notice: This article is laboratory and educational information only. It is not medical or legal advice, and it does not include how-to-use instructions. BlueNex Labs materials are research use only and are not intended for human or veterinary use. Research-use-only labelling is not a Health Canada authorization.
Retatrutide (LY3437943) is an investigational triple agonist at GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. As of the status check for this article, it is not FDA-approved and is not a Health Canada-authorized medicine. This page tracks public regulatory status. It is not the shop listing.
What “investigational” means
Public sources describe an IND-stage program and Phase 3 work under the TRIUMPH name. An advisory article or blog that calls retatrutide “approved” is incorrect until a regulator issues that decision. An NDA timeline in secondary media is a forecast, not a catalogue fact.
What trials are designed to measure
Registered studies evaluate metabolic endpoints such as glycemic markers and body-weight change in defined cohorts, plus safety. Reporting a trial endpoint is not the same as advertising a consumer outcome. Published phase 2 papers are cited on retatrutide clinical trial notes. This page does not repeat uncited sponsor readout figures.
Laboratory lots
The 10 mg, 20 mg, and 30 mg research fills are separate listings: retatrutide 10 mg, retatrutide 20 mg, and retatrutide 30 mg. Certificate rows are 10 mg, 20 mg, and 30 mg. Those pages are for laboratory purchasing. They are not Lilly trial drug and they are not a prescription product.
Catalogue cross-reference
A research vial on this catalogue is not the investigational trial supply. Confirm lot identity on the COA before an assay, and do not treat secondary media timelines as a purchasing specification.
Orders ship inside Canada only after Interac e-Transfer checkout. Sold-out SKUs remain listed and cannot be added to the cart. Match each vial to its own Certificate of Analysis when a lot is published. Research use only. Not for human or veterinary use.
References
This note does not add a separate citation list. Named papers, when the body links them, stay in the text above.
Research use only. BlueNex Labs does not provide medical or veterinary advice. Confirm your institution’s policies before purchase. Lot-file rules for this note are on the documentation standards page. Scientific lead: Alice Kay, Ph.D.